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Therapeutic vaccines against tumors associated with human papillomaviruses (HPV) should elicit cellular immune
responses against early HPV antigens, primarily the oncoproteins E7 and E6. Because of safety concerns, the direct use of
an unmodified oncogene is impossible in human DNA vaccination. Therefore, we introduced three point mutations into the
pRb-binding site of HPV16 E7 oncogene to eliminate its transformation potential. The resultant gene was denoted E7GGG.
The rates of expression and the cellular localization of E7 and E7GGG proteins were comparable. In immunization-challenge
experiments, the efficacy of plasmids containing the E7, E7GGG, or fusion genes of HPV16 E7, viz. L1DCE71–60 (M. Muller et
al., 1997, Virology 234, 93–111), and Sig/E7/LAMP-1 (T. C. Wu et al., 1995, Proc. Natl. Acad. Sci. USA 92, 11671–11675), was
compared. While tumors developed in all animals immunized with the wild-type E7 gene, a significant proportion of mice
remained tumor-free after vaccination with the E7GGG gene. The fusion gene L1DCE71–60 induced negligible protection, but
Sig/E7/LAMP-1 conferred the highest protection. Intradermal immunization by gene gun proved superior to i.m. inoculation.
In “therapeutic” experiments, a 1-day delay between inoculation of oncogenic cells and the start of DNA immunization
resulted in partial therapeutic effect, but a 3-day delay produced a substantially lower immunization effect. A combination of
Sig/E7/LAMP-1 and E7GGG genes did not enhance the immune response. These results demonstrate a significant
enhancement of HPV16 E7 immunogenicity after mutagenesis of the pRb-binding site, but the mutated E7 gene did not excel
the Sig/E7/LAMP-1 fusion gene. © 2001 Academic Press
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Since human papillomaviruses (HPV) have been iden-
tified as the key etiological agent of cervical carcinoma
(CC), both prophylactic and therapeutic anti-HPV vac-
cines are at present being developed. While preventive
immunization is based on the structural L1 and L2 pro-
teins of HPV and should result in induction of neutralizing
antibodies to secure their presence at the portal of virus
entry, therapeutic vaccination is aimed at eliciting cellu-
lar immune responses to viral E7 and/or E6 oncopro-
teins. These oncoproteins are responsible for both the
oncogenic transformation of cells and maintenance of
the transformed state (Galloway and McDougall, 1996).
E6 and E7 are the only viral proteins continually ex-
pressed in CC cells as well as in cell lines derived from
these tumors. It has been demonstrated in rodent mod-
els that E7 and E6 oncoproteins are targets for host
immune responses (Chen et al., 1992, 1991). Moreover,
protection against tumor cells expressing the HPV16 E7
oncoprotein has been achieved by immunization with
E7-transfected nontumorigenic cells (Chen et al., 1991),
E7 recombinant vaccinia virus (Meneguzzi et al., 1991),
E7-derived synthetic peptides (Feltkamp et al., 1993), E7
recombinant protein (Fernando et al., 1999; Hariharan et1 To whom reprint requests should be addressed. Fax: 1420-2-21
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231al., 1998), E7-containing chimeric virus-like particles
(CVLPs) (Greenstone et al., 1998; Peng et al., 1998; Scha-
fer et al., 1999) and suicide-gene-modified tumor cells
(Vonka et al., 1998). In patients infected with HPV type 16,
which is found in CC the most frequently, cell-mediated
immunity to the E7 protein has been demonstrated (de
Gruijl et al., 1996; Kadish et al., 1994; van Driel et al.,
1996).
DNA immunization represents a new approach in vac-
cination against both infectious and malignant diseases.
Immunization with E6 and/or E7 genes has been shown
to protect against cottontail rabbit papillomavirus (CRPV)
(Sundaram et al., 1998) and against HPV16 E6/E7-trans-
formed hamster (Smahel et al., 1999) and mouse (Bube-
nı´k et al., 1999) cells. However, the E6 and E7 genes of
oncogenic HPV types are real oncogenes and for safety
reasons cannot be utilized for DNA vaccination of hu-
mans. It has been shown that the transformation poten-
tial of the E7 oncoprotein is mainly localized in its pRb-
binding site. Mapping of this region has shown that
mutations C24G (Edmonds and Vousden, 1989), E26G
(Edmonds and Vousden, 1989), and D21G (Heck et al.,
1992) can substantially reduce or completely abolish pRb
binding and transformation activity of the E7 oncoprotein.
Immunogenicity of the HPV16 E7 protein has recently
been markedly improved by fusing it with two parts of the
lysosome-associated membrane protein 1 (LAMP-1).
This has resulted in localization of the Sig/E7/LAMP-1
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232 SˇMAHEL ET AL.fusion protein into the endosomal and lysosomal com-
partments and enhancement of presentation of the E7
antigen by MHC class II molecules (Wu et al., 1995).
Increased stimulation of CD41 T cells has apparently
given more efficient protection against tumor cells ex-
pressing the E7 protein. This effect has been observed
both after immunization with recombinant vaccinia virus
(Lin et al., 1996) and after DNA immunization with the
Sig/E7/LAMP-1 gene (Chen et al., 1999; Ji et al., 1999).
Chimeric virus-like particles containing a fusion pro-
tein consisting of E7 and papillomavirus capsid protein
L1 (Peng et al., 1998; Schafer et al., 1999) or L2 (Green-
stone et al., 1998) have been used not only for stimulation
of neutralizing antibody production but also for the de-
livery of E7 antigen into antigen-presenting cells (APC)
and induction of protection against E7-expressing tumor
cells. However, to the best of our knowledge, it has not
yet been tested whether fusion with a gene coding for a
capsid protein can influence E7 immunogenicity in DNA
immunization.
In this study, we introduced three point mutations into
the pRb-binding site of the E7 protein and compared this
FIG. 1. Mutagenesis of the HPV16 E7 gene. AAs 21 (Asn), 24 (Cys),
nd 26 (Glu) were replaced by Gly; the three point mutations were
ntroduced by primer E7GGG. The positions mutated are underlined.FIG. 2. Plasmids used for DNA immunization. HPV16 E7, E7GGG, L1DCE71mutated gene with the unmodified gene as well as with
two E7 fusion genes, viz. Sig/E7/LAMP-1 (Wu et al., 1995)
and L1CDE71–60 (Muller et al., 1997), in immunization
experiments.
RESULTS
Detection of E7 proteins by immunofluorescence and
immunoblotting
Mutagenesis of the HPV16 E7 gene (Fig. 1) and con-
struction of pBSC/E7, pBSC/E7GGG, pBSC/L1E7, and
pBSC/E7LAMP (Fig. 2) were performed as described
under Material and Methods. Expression of E7 proteins
in cells transfected with the plasmids constructed was
tested by immunofluorescence (Fig. 3) and immunoblot-
FIG. 3. Immunofluorescence detection of E7 antigen expressed from
plasmids constructed. NIH 3T3 cells were grown on slides and trans-
fected with the plasmids. Immunostaining with anti-E7 TVG710Y mouse
monoclonal antibody was performed in paraformaldehyde-fixed cells 2
days later.-60, and Sig/E7/LAMP-1 genes were cloned into the XhoI site of pBSC.
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233IMMUNIZATION WITH HPV16 E7 GENESting (Fig. 4). In accordance with published data, predom-
inant cellular staining was nuclear, granular cytoplasmic,
and diffuse cytoplasmic for pBSC/E7, pBSC/E7LAMP, and
pBSC/L1E7, respectively. Mutagenesis of the E7 gene did
not change the cellular localization, nor the amount of
the protein produced. The size of E7GGG protein is
slightly reduced as determined by electrophoresis.
Preventive immunization
The two experiments performed showed essentially
the same tendency; their results have been combined in
Table 1. After i.m. immunization, all mice that had re-
ceived control plasmid pBSC or pBSC/E7 developed tu-
mors. A significant reduction of tumor formation was
recorded after immunization with pBSC/E7LAMP: 6 of 18
animals remained without tumor. The immunization ef-
fect of pBSC/L1E7 was negligible, but immunization with
pBSC/E7GGG delayed tumor formation in some mice
and 3 mice were protected completely. After i.d. immu-
nization, the results were similar to those following i.m.
FIG. 4. Immunoblotting of E7 antigen expressed from plasmids con-
tructed. 293T cells were grown on dishes and transfected with the
lasmids. Two days later, proteins from about 2 3 105 lysed cells were
separated by 12% SDS–PAGE and transferred onto nitrocellulose mem-
brane. Detection was performed with monoclonal anti-E7 antibody
(Zymed).
T
Tumor Formation in Preve
Plasmid
i.m.
No. of mice No. of tumors
Nonimmunized 17 17
pBSC 17 17
BSC/E7 18 18
BSC/E7GGG 18 15
pBSC/L1E7 18 17
pBSC/E7LAMP 18 12
Note. Mice were immunized with two doses of plasmids and the
experiments.
a Compared with pBSC.inoculation for plasmids pBSC, pBSC/E7, and pBSC/
L1E7; i.e., there was very weak or negligible protection.
Significant protection was, however, induced not only by
pBSC/E7LAMP (83%) but also by pBSC/E7GGG (53%).
Therapeutic immunization
The plasmids found most efficient in preventive immu-
nization, pBSC/E7GGG and pBSC/E7LAMP, were chosen
for therapeutic immunization. In the first experiment, in
which immunization started 1 day after TC-1 cell inocu-
lation, no significant reduction in tumor formation was
recorded after i.m. inoculation (Fig. 5A). Only one mouse
(in the group immunized with a combination of the two
plasmids) remained tumor-free. Intradermal immuniza-
tion by gene gun again proved to be more efficient—4
out of 5 mice stayed tumor-free in groups of mice immu-
nized either with pBSC/E7GG or pBSC/E7LAMP alone or
with their mixture (Fig. 5B).
In the second therapeutic experiment, in which immu-
nization started 3 days after TC-1 cell inoculation, tumors
developed in all animals (Fig. 6). However, tumor growth
was slowed down in the immunized groups. The small-
est tumors were recorded after immunization with pBSC/
E7LAMP. Mean tumor size after vaccination with pBSC/
E7GGG or a mixture of pBSC/E7LAMP and pBSC/E7GGG
did not differ markedly.
DISCUSSION
In DNA immunization against malignancies, the use of
unmodified oncogenes is unacceptable because of the
potential risk of oncogenic transformation of the cells
transduced. In this study we introduced three point mu-
tations into the pRb-binding site of HPV16 E7 oncopro-
tein. It has been previously demonstrated that any of
these mutations separately can diminish or completely
abolish pRb binding and the transformation ability of E7
protein (Edmonds and Vousden, 1989; Heck et al., 1992).
Two of them were previously used for inactivation of
munization Experiments
i.d.
a No. of mice No. of tumors P a
17 17
15 14
18 18
23 17 8 0.007
00 17 15 1.000
19 18 3 ,0.001
cells were administered. The table summarizes results from twoABLE 1
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234 SˇMAHEL ET AL.HPV16 E7 and HPV18 E7 proteins in recombinant vac-
cinia virus (Boursnell et al., 1996) examined in a clinical
trial (Borysiewicz et al., 1996).
Our results suggest that mutagenesis in the pRb-bind-
ing site of E7 significantly enhanced the immunogenicity
of this protein. The reasons for this are not quite clear.
Several alternative explanations might be considered: (i)
In cells transfected in vitro with plasmids carrying either
he wild-type E7 or the mutated E7GGG gene, the cellular
ocalization of the respective proteins was the same.
his failed to provide any evidence that the mutated
rotein was processed differently. (ii) Neither was the
igher immunogenicity of the mutated protein due to its
nhanced production or degradation, since the amounts
f both E7 proteins produced in the transfected cells
ere nearly identical. However, this statement should be
FIG. 5. Tumor formation in the first therapeutic experiment. Mice
were inoculated with 104 TC-1 cells and immunized i.m. (A) or i.d. (B) on
ays 1 and 8.aken with caution, because in vivo the situation might be
ifferent. (iii) It does not seem likely, either, that the threesubstitutions directly enhanced the immunogenicity of
the E7 protein. The E7 peptide consisting of aminoacids
(AAs) 21–28, which contains the three AAs substituted in
E7GGG, has been shown to bind H-2Kb molecules and
stimulate CD81 cytotoxic T lymphocytes (CTL) capable of
rotecting C57BL/6 mice against tumor cells expressing
7 (Bauer et al., 1995; Sadovnikova et al., 1994). Further-
ore, it has been reported that substitution of anchor
As in CTL epitopes represented by synthetic peptides
an strengthen the peptide binding with MHC class I
olecules and enhance immune responses (Lipford et
l., 1995; Parkhurst et al., 1996; Pogue et al., 1995; Vier-
oom et al., 1998). However, in the present experiments
e did not mutate anchor AAs but AAs that most prob-
bly bind to the T-cell receptor (TCR) (Shibata et al.,
992). It has been shown that replacement of such AAs
an activate the CTL response (Zaremba et al., 1997), but
it is likely that the substitutions introduced in E7GGG
(Asp, Cys, and Glu replaced by Gly) modified the AAs
21–28 epitope to such an extent that the specificity of the
epitope was changed. (iv) Therefore, we propose a dif-
ferent explanation for the increased E7GGG immunoge-
nicity. The phenomenon might be associated with the
failure of the E7GGG protein to bind to pRb. According to
some past evidence, it is likely that direct transfection of
dendritic cells (DC) plays an important role in the im-
mune responses induced by DNA vaccination (Casares
et al., 1997). It has also been suggested that wild-type E7
expression in DC suppresses their capability of antigen
presentation because of inhibition of DC differentiation
(Frazer et al., 1999). The modified E7GGG, whose capa-
bility of binding to pRB is eliminated, should be free of
such inhibitory activity, thus enabling its enhanced pre-
sentation.
FIG. 6. Tumor growth in the second therapeutic experiment. Mice
were inoculated with 2 3 104 TC-1 cells and immunized i.d. on Days 3
and 10. Tumors developed in all animals.
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235IMMUNIZATION WITH HPV16 E7 GENESShi et al. (1999) also prepared a mutated E7 gene with
little transforming activity and enhanced immunogenicity,
but they mutated cysteines in two zinc-binding motifs.
These alterations led to rapid degradation of the E7
protein by proteasomes resulting in enhanced presenta-
tion by MHC class I molecules and augmented CTL
response.
In our DNA immunization experiments, we furthermore
compared the mutated E7GGG with two E7 fusion genes,
Sig/E7/LAMP-1 (Wu et al., 1995) and L1DCE71-60 (Muller
et al., 1997). Although—as already mentioned—a signif-
icant enhancement of immunogenicity was recorded for
E7GGG, the best immunization efficacy was obtained
with Sig/E7/LAMP-1. Ji et al. (1999) reported data similar
to our results with Sig/E7/LAMP-1 and E7 genes, but they
obtained a higher degree of protection than we did. We
speculate that these differences might have partially
been due to the higher immunization dose of plasmids
they used (2 vs. 1 mg). Moreover, the plasmids used by Ji
t al. contained, in addition to the E7 and Sig/E7/LAMP-1
enes, also the NeoR gene, i.e., a gene that is also
xpressed in the challenging TC-1 cells. Therefore, the
eoR product could have functioned in their system as
an additional tumor antigen.
The induction of neutralizing antibodies by immuniza-
tion with the cottontail rabbit papillomavirus L1 gene
(Sundaram et al., 1997; Ulmer et al., 1996) suggests that
VLPs can be formed after application of the correspond-
ing plasmid. Very efficient E7-specific anti-tumor protec-
tion has been induced by immunization with CVLPs con-
sisting of the L1DCE71-60 protein (Schafer et al., 1999). In
our DNA-immunization experiments, protection after vac-
cination with the L1DCE71-60 fusion gene was weak. This
difference may be due to the low level of formation of
CVLPs after immunization with the plasmid. We were
able to detect the L1DCE71-60 protein only after highly
efficient transfection of 293T cells (Fig. 4). When the
efficiency was decreased we did not record a propor-
tionally reduced expression of the L1DCE71-60 protein, but
total loss of protein (data not shown). We suppose that
the formation of CVLPs is only possible after sufficient
expression of the L1DCE71-60 protein and that particle
ormation stabilizes the protein.
In our experiments, much more efficient immune re-
ponse was induced by i.d. administration of plasmids
sing the gene gun than by i.m. injection, although 100
imes less DNA was applied by the gene gun. Similar
esults have also been published by other groups (Eisen-
raun et al., 1993; Fynan et al., 1993; Pertmer et al., 1995).
t is supposed that direct delivery of plasmid-coated gold
articles into APC is responsible for this effect (Casares
t al., 1997). Moreover, while i.m. DNA immunization has
nduced predominantly Th1 response characterized by
roduction of IgG2a antibodies and IFN-g, i.d. delivery ofplasmids by gene gun has resulted in mixed response;
i.e., attributes of both Th1 (CTL, IFN-g) and Th2 (IgG1,IL-4) response were recorded (Pertmer et al., 1996).
Since Hung et al. (1998) have shown that the simulta-
eous induction of Th1 and Th2 responses is necessary
or optimal antitumor immunity, i.d. immunization by the
ene gun may be the superior method of DNA vaccina-
ion against malignant diseases.
To summarize, we showed that mutagenesis of the
Rb-binding site of HPV16 E7 oncoprotein significantly
nhanced its immunogenicity. However, the fusion gene
ig/E7/LAMP-1 proved to be more efficient in DNA im-
unization experiments.
MATERIALS AND METHODS
nimals and cell lines
Five-week-old female C57BL/6 mice (H-2b) (Charles
River, Germany) were used in the immunization experi-
ments. TC-1 tumor cells, prepared by transformation of
C57BL/6 primary mouse lung cells with HPV16 E6/E7
oncogenes and activated H-ras, were kindly provided by
T.-C. Wu (Johns Hopkins University, Baltimore, MD). To
verify the expression of E7 proteins, mouse NIH 3T3
fibroblasts and human kidney 293T cells (kindly provided
by J. Kleinschmidt, DKFZ, Heidelberg, Germany) were
transfected. Cells were grown in Dulbecco’s modified
Eagle’s medium (D-MEM) (Sevac, Prague, Czech Repub-
lic) supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin.
Plasmids
Plasmid pEA16E7 (kindly provided by F. Momburg,
DKFZ, Heidelberg, Germany) contains the HPV16 E7 on-
cogene. pVLL1/E7N#265 (kindly provided by M. Muller,
Loyola University Chicago, Maywood, IL) contains a
gene coding for a fusion protein consisting of the HPV16
L1 major capsid protein lacking 34 AAs on its C-terminus
and the 60-AA N-terminus of HPV16 E7 protein. pCMV-
neoSig/E7/LAMP-1 (kindly provided by T.-C. Wu, Johns
Hopkins University, Baltimore, MD) carries a fusion gene
composed of the signal sequence of LAMP-1, a complete
HPV16 E7 gene and the C-terminus of LAMP-1 (Chen et
al., 1999; Wu et al., 1995). pBCMGNeo.mIL-2 (Kara-
suyama et al., 1989) was kindly provided by H. Kara-
suyama (Basel Institute for Immunology, Switzerland).
Mutagenesis of E7 gene
The HPV16 E7 oncogene was excised from pEA16E7
with EcoRI and BamHI and cloned into pBluescript-SK
(Stratagene, La Jolla, CA) between the EcoRI and the
BamHI sites. The gene was mutated using the Chame-
leon Mutagenesis Kit (Stratagene) to generate plasmid
pBS/E7GGG. Three point mutations were introduced into
oligonucleotide CATTTAATTGCCCATAACCGTAGAGAC-
CAGTTGTCTCTGG (HPV16 nt 649–610) as indicated by
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236 SˇMAHEL ET AL.the nucleotides underlined (Fig. 1). These mutations re-
sulted in substitution of three AAs in the E7 protein:
D21G, C24G, and E26G. The resultant gene, denoted
E7GGG, was sequenced to verify its faultlessness.
Construction of plasmids for immunization
A diagram of the plasmids prepared is shown in Fig. 2.
An “empty” plasmid, denoted pBSC, was constructed as
follows: fragment XbaI–BamHI, containing cDNA of
mouse interleukin 2 (mIL-2), the immediately early pro-
moter of human cytomegalovirus, and the second intron
and polyadenylation signal of rabbit b-globin gene was
igested out of pBCMGNeo.mIL-2 and cloned between
he XbaI and BamHI sites of plasmids pBluescript-SK
nd pBK-CMV (Stratagene). The resulting plasmids were
enoted pBSC/IL-2 and pBK-CMV/IL-2, respectively.
ragment XhoI from pBSC/IL-2 containing cDNA of mIL-2
nd the polyadenylation signal was replaced by fragment
hoI–SalI from pBK-CMV/IL-2 bearing only the polyade-
ylation signal.
The E7 and E7GGG genes were then excised with
amHI and EcoRI from pEA16E7 and pBS/E7GGG, re-
pectively, and cloned into pBK-CMV between the BamHI
nd EcoRI sites. The genes were then digested out with
alI and XhoI and inserted into the XhoI site of pBSC. The
L1DCE71-60 gene was excised with BglII and HindIII from
pVLL1/E7N#265 and cloned into pBK-CMV between the
BamHI and the HindIII sites. The gene was then digested
out with SalI and XhoI and inserted into the XhoI site of
pBSC. The Sig/E7/LAMP-1 gene, together with intron,
was excised with SalI and BamHI from pCMVneoSig/E7/
LAMP-1 and cloned into pBK-CMV between the SalI and
the BamHI sites. The gene and intron were then digested
out with SalI and XhoI and inserted between the SalI and
the XhoI sites of pBSC.
Plasmids to be used in immunization experiments
were propagated in Escherichia coli, XL1-blue strain,
cultured in Luria Broth medium with 100 mg/ml of ampi-
cillin added. For i.m. inoculation, plasmid DNA was ex-
tracted by alkaline lysis followed by two CsCl gradient
purifications. The DNA isolated was dissolved in phos-
phate-buffered saline (PBS) and stored at 220°C. Plas-
mids for coating onto gold particles and delivery by gene
gun (see below) were purified with a Qiagen Plasmid
Maxi kit (Qiagen, Hilden, Germany).
Preparation of cartridges for gene gun
Plasmid DNA was coated onto 1-mm gold particles
(Bio-Rad, Hercules, CA) by the procedure recommended
by the producer. In brief, 25 mg of gold particles was
sequentially mixed with 100 ml of 0.05 M spermidine
Sigma, St. Louis, MO), 50 mg of plasmid DNA, and 100 ml
of 1 M CaCl2 (Sigma). The mixture was precipitated at
room temperature for 10 min and washed three times in
absolute ethanol (Merck, Darmstadt, Germany). The pel-
t
wlet of particles was resuspended in 3.5 ml of 0.05 mg/ml
polyvinylpyrrolidone (Bio-Rad) in absolute ethanol. The
suspension was loaded into Gold-Coat tubing and al-
lowed to settle in a horizontal position for 3 min in a
Tubing Prep Station (Bio-Rad). Ethanol was removed and,
while rotating, the tube was dried by flowing nitrogen.
The dried tubing was cut into 0.5-in. cartridges and these
were stored in a tightly capped vial, containing a desic-
cant pellet, at 4°C. Each cartridge contained 1 mg of DNA
oated onto 0.5 mg of gold particles.
etection of E7 antigen by immunofluorescence
NIH 3T3 cells were grown on slides and transfected
ith plasmids by modified calcium-phosphate precipita-
ion (Chen and Okayama, 1988). Two days after transfec-
ion cells were fixed with 4% paraformaldehyde for 10
in and permeabilized with 1% Triton X-100 for 3 min. E7
ntigen was stained with TVG710Y mouse monoclonal
ntibody (Santa Cruz Biotechnology, Santa Cruz, CA) and
econdary SwaM-FITC antibody (Sevac, Prague, Czech
epublic).
etection of E7 antigen by immunoblotting
293T cells grown in 10-cm dishes were transfected
ith plasmids by modified calcium-phosphate precipita-
ion (Chen and Okayama, 1988). Two days after transfec-
ion the cells were washed twice with ice-cold PBS,
rypsinized, and resuspended in lysis buffer (4% SDS,
0% glycerol, 10% mercaptoethanol, 2 mM EDTA, 100 mM
ris–HCl, pH 8; Kaufmann et al., 1997). Proteins from
about 2 3 105 cells were further analyzed by 12% SDS–
AGE. Separated proteins were electroblotted onto a
itrocellulose membrane, incubated with monoclonal
nti-E7 antibody (clone 8C9, Zymed, San Francisco, CA)
nd, subsequently, with secondary peroxidase-labeled
ntibodies. Blots were stained using the ECL Plus sys-
em (Amersham, Little Chalfont, England).
mmunization/challenge experiments
Two procedures were used for immunization of mice
8 and 10 per group in the first and second experiment,
espectively) with pBSC, pBSC/E7, pBSC/E7GGG, pBSC/
1E7, or pBSC/E7LAMP: i.m. injection of 100 mg of plas-
mid DNA in 50 ml of PBS into quadriceps femoris or i.d.
administration of 1 mg of plasmids by gene gun, at a
ischarge pressure of 400 psi, into shaven skin of abdo-
en. Immunization was repeated 4 weeks later and after
nother 2 weeks the animals were challenged s.c. into
heir backs with 104 TC-1 cells suspended in 100 ml of
BS. Unimmunized mice received the same TC-1 dose inhe same manner. Tumor growth was monitored twice a
eek by palpation.
p
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Mice were inoculated with TC-1 cells and then immu-
nized. In the first experiment, 104 TC-1 cells were in-
jected s.c. into the back (five mice per group) and 1 and
8 days later the animals were immunized i.m. or i.d. with
pBSC, pBSC/E7GGG, or pBSC/E7LAMP or with a combi-
nation of pBSC/E7GGG and pBSC/E7LAMP. In the case
of i.m. immunization by the pBSC/E7GGG 1 pBSC/
E7LAMP combination, the plasmids, 100 mg each, were
mixed and injected in 50 ml.; combined i.d. immunization
by gene gun consisted of two shots of gold particles
coated with 1 mg pBSC/E7GGG or pBSC/E7LAMP in the
first and second shot, respectively. Both plasmids were
administered into the same site of abdominal skin.
In the second experiment, 2 3 104 TC-1 cells were
injected s.c. into the backs of mice (10 per group) and 3
and 10 days later the animals were immunized i.d. with
pBSC, pBSC/E7GGG, or pBSC/E7LAMP or with pBSC/
E7GGG and pBSC/E7LAMP combined. For the combined
immunization, gold particles simultaneously coated with
equal amounts of pBSC/E7GGG and pBSC/E7LAMP
were prepared. All groups immunized received 1 mg
plasmid DNA per dose. Again, naive age-matched mice
were used as controls. Tumor size was measured twice
a week.
Statistical analysis
Data obtained after preventive immunization were an-
alyzed in 2 3 2 contingency tables by two-tailed Fisher’s
exact test. A difference between groups was considered
statistically significant if P , 0.05. Calculations were
erformed using Prism software, Version 3.0 (GraphPad
oftware, Inc., San Diego, CA).
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